Please login to the form below

Not currently logged in
Email:
Password:

Charles Morris appointed chief development officer at ImmunoGen

Previously worked in oncology for Allos, Cephalon and AstraZeneca

Immunogen has appointed Dr Charles Morris as the company's chief development officer.

Dr Morris, who joins from Allos Therapeutics, will oversee all aspects of product development for the US cancer-focused biotech.

Its pipeline includes the investigational compounds IMGN901 - in phase II testing for the treatment of small-cell lung cancer - IMGN853, in phase I for the treatment of ovarian, lung, and other cancers that over-express folate receptor 1, and IMGN529 - in phase I testing for the treatment of non-Hodgkin's lymphoma.

ImmunoGen said it also expects to advance a fourth compound into clinic studies in 2013.

"Charlie has extensive experience leading the strategic development and registration of novel oncology compounds — expertise essential to ImmunoGen with our advancing and expanding product pipeline," said Daniel Junius, president and CEO of the company.

“We are excited to have Charlie joining ImmunoGen at this important time in our transition to being a product development company."

Dr Morris was previously executive VP and chief medical officer at Allos for two years, holding similar responsibilities as to his current role.

Prior to joining Allos, which was acquired in September by Spectrum Pharmaceuticals, he served as VPof  worldwide clinical research at US biopharma company Cephalon, where he helped with the development of oncology drug Treanda (bendamustine).

He has also spent time with AstraZeneca, where his roles included VP, clinical development projects in oncology.

27th November 2012

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics